Major diabetes study tests new combo injection against standard care
NCT ID NCT07307235
Summary
This study aims to see if a newer combination injection (iGlarLixi) works better and is safer than standard insulin treatments for adults in China whose type 2 diabetes is not well controlled on pills alone. About 1,300 participants will be randomly assigned to receive either the new injection or standard care for 24 weeks. Researchers will mainly track changes in long-term blood sugar levels (HbA1c), weight, and episodes of low blood sugar.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.